Norovirus Genogroup I Genotype 4 Virus-Like Particle (GI.4 VLP)

Norovirus Genogroup I Genotype 4 Virus-Like Particles (GI.4 VLPs) are recombinant, non-infectious protein assemblies that mimic the icosahedral structure of the native GI.4 norovirus [1]. They are composed of 180 copies of the major capsid protein VP1, which contains a shell (S) domain for structural integrity and a protruding (P) domain responsible for host cell recognition through binding with Histo-blood group antigens (HBGAs) [2][3]. Because noroviruses are difficult to culture in vitro, VLPs serve as the primary platform for vaccine development and structural biology studies [4]. In the context of human health, GI.4 is a significant genotype within Genogroup I associated with epidemic and sporadic outbreaks of acute gastroenteritis [5]. Therapeutic strategies focusing on GI.4 VLPs typically involve their inclusion in multivalent vaccine formulations alongside other high-prevalence strains like GI.1 and GII.4. These vaccines aim to elicit high titers of serum and mucosal antibodies that interfere with the virus's ability to dock onto intestinal cells, providing a preventive measure against the severe dehydration and vomiting characteristic of norovirus infection [6]. Citations: [1] Prasad et al., 1999 (Science); [2] Tan and Jiang, 2005 (Journal of Virology); [3] Atmar et al., 2011 (NEJM); [4] Vinje, 2015 (Journal of Clinical Microbiology); [5] Parra, 2019 (Viruses); [6] Leroux-Roels et al., 2018 (Vaccine).

Other names

Norovirus GI.4 capsid proteinNorovirus GI.4 VP1Chiba virus-like particleNorovirus Genogroup I Genotype 4 capsidGI.4 Norovirus antigen

Vaccine candidates utilizing GI.4 VLPs function by presenting the native antigenic structure of the norovirus capsid to the host immune system without the risk of infection. This induces the production of neutralizing antibodies, specifically those that block the interaction between the viral P domain and host Histo-blood group antigens (HBGAs), thereby preventing viral entry into enterocytes [1][3][5].